NEJ009 trial: A randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation.

Authors

Akira Inoue

Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan

Akira Inoue , Yukio Hosomi , Makoto Maemondo , Shunichi Sugawara , Terufumi Kato , Kazuhisa Takahashi , Yuka Fujita , Akihiko Gemma , Toshiyuki Harada , Satoshi Oizumi , Koichi Minato , Satoshi Morita , Toshihiro Nukiwa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).

First Author: Atsushi Nakamura

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Final overall survival results of NEJ002, a phase 3 trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

First Author: A. Inoue

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.

First Author: Helena Alexandra Yu

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).

First Author: Wenfeng Fang